Canadian Pharma, Biotech and Life Sciences Stocks

12 Canadian Crypto and Blockchain Stocks to Follow

Hot money. Ask anyone in the capital markets who has taken a meeting in the past two months, blockchain is on everyone’s lips. And it’s already been a bit of a rollercoaster ride, from the dizzying early highs of HIVE Blockchain to the aborted IPO of NextBlock Global. The most immediate paral ...

13 Canadian Crypto and Blockchain Stocks to Follow

Hot money. Ask anyone in the capital markets who has taken a meeting in the past two months, blockchain is on everyone’s lips. And it’s already been a bit of a rollercoaster ride, from the dizzying early highs of HIVE Blockchain to the aborted IPO of NextBlock Global. The most immediate paral ...

ProMetic Life Sciences has 183% upside, Canaccord Genuity says

Prometic Life Sciences CEO Pierre Laurin The company needs to be wary of its burn rate, but Canaccord Genuity analyst Neil Maruoka sees plenty of upside in ProMetic Life Sciences (TSX:PLI). This morning, PromMetic reported what it described as positive interim six-month clinical data from its con ...

There’s still some upside in Immunovaccine, Mackie Research says

The stock is up more than 140 per cent year to date, but Mackie Research Capital analyst Andre Uddin thinks Immunovaccine (TSX:IMV) still has a ways to go. This morning, Immunovaccine announced it will expand its collaboration with Leidos. The pair are developing peptide-based malaria vaccine cand ...

How mutual fund investors are being left out of the pot stock rally

According to TD, funds that haven’t added Canopy Growth Corp. to their portfolios are lagging the benchmark index by about 7 basis points since March ...

Centric Health has “substantial upside”, Canaccord Genuity says

The company’s recent quarter revealed headwinds that may continue for longer than he initially expected, but Canaccord Genuity analyst Neil Maruoka thinks Centric Health (TSX:CHH) is undervalued. On Tuesday, Centric Health reported its Q3, 2017 results. The company earned $248,000 on revenue of ...

Canopy Growth Corp. is in a league of its own, GMP says

A second quarter he characterizes as a “slight miss” isn’t dampening GMP Securities analyst Martin Landry’s enthusiasm for Canopy Growth Corp (TSX:WEED). On Tuesday, Canopy Grwoth Corp reported its Q2, 2018 results. The company lost $1.61-million on revenue of $17.6-million, a topline that ...

Canopy Growth Corp CEO says company can win against the black market

Bruce Linton on BNN, November 14. 2017 Is the black market an unseen force that will forever drag down the price per gram commanded by Licensed Producers? Far from it, says the CEO of the world’s largest pot play, Canopy Growth Corp. (TSX:WEED). Canopy boss Bruce Linton was on BNN Tuesday, wher ...

Centric Health has 79% upside: Canaccord Genuity

Ahead of the company’s third quarter results, Canaccord Genuity analyst Neil Maruoka is feeling bullish about Centric Health (TSX:CHH). Next week, Centric Health will report its Q3, 2017 results. Maruoka expects the company will generate EBITDA of $4.9-million on a topline of $45.1-million, slig ...

Still too many unknowns about the marijuana sector to invest, National Bank’s Tetrault says

Rob Tetrault on BNN. There are a lot of unknowns still to be decided about Canada’s cannabis trade, says National Bank Financial money manager Rob Tetrault, but the size of the market is probably not one of them. And with the whole industry likely topping out at around $10 billion once the dust ...